Meeting
2013 ASCO Annual Meeting
Circulating cytokines and angiogenic factors (CAF) as markers of clinical response in the study of trametinib (T) plus gemcitabine (G) versus placebo (P) plus gemcitabine for patients (pts) with untreated metastatic adenocarcinoma of the pancreas (MEK113487).
Authors
John Heymach
The University of Texas MD Anderson Cancer Center, Houston, TX
John Heymach , Hai T. Tran , Andrew B. Nixon , Herbert Hurwitz , Jeffrey R. Infante , Robert C. Gagnon , Klaudia Steplewski , Ngocdiep T. Le , Yuan Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT01231581
Citation
J Clin Oncol 31, 2013 (suppl; abstr 4042)
DOI
10.1200/jco.2013.31.15_suppl.4042
Abstract #
4042
Poster Bd #
16D
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Correlation of circulating IL-8 levels with improved overall survival in advanced pancreatic cancer patients in response to antisense OT-101 (trabedersen) therapy.
First Author: Vuong N. Trieu
Poster
2013 Gastrointestinal Cancers Symposium
A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.
First Author: Jeffrey Infante
Poster
2016 ASCO Annual Meeting
Role of inflammation gene polymorphisms on pain and response to radiotherapy in multiple myeloma patients with painful bone destructions.
First Author: Milda Rudzianskiene
Poster
2023 ASCO Annual Meeting
Effects of yoga vs placebo on inflammation among cancer survivors: A nationwide multicenter phase III randomized controlled trial (RCT).
First Author: Po-Ju Lin